BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21682596)

  • 1. Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.
    Lai P; Weng J; Lu Z; Guo R; Luo C; Wu S; Ling W; Geng S; Du X
    DNA Cell Biol; 2011 Dec; 30(12):1019-25. PubMed ID: 21682596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning.
    Poloni A; Sartini D; Emanuelli M; Trappolini S; Mancini S; Pozzi V; Costantini B; Serrani F; Berardinelli E; Renzi E; Olivieri A; Leoni P
    Cytokine; 2011 Mar; 53(3):376-83. PubMed ID: 21211989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation.
    Kotani A; Ishikawa T; Matsumura Y; Ichinohe T; Ohno H; Hori T; Uchiyama T
    Blood; 2001 Nov; 98(10):3162-4. PubMed ID: 11698307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia.
    Lv M; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X; Mo X
    Front Med; 2019 Dec; 13(6):667-679. PubMed ID: 31512033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
    Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
    Front Immunol; 2020; 11():575492. PubMed ID: 33193367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in binding activity of T cell transcription factor CD28 responsive element binding complex (CD28RC) following allogeneic bone marrow transplantation.
    Tanaka J; Mori A; Ota S; Yamamoto Y; Kobayashi S; Hashino S; Asaka M; Imamura M
    Eur J Haematol; 2000 May; 64(5):333-9. PubMed ID: 10863979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
    Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
    Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation.
    Yoshizawa S; Umezu T; Saitoh Y; Gotoh M; Akahane D; Kobayashi C; Ohyashiki JH; Ohyashiki K
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary gene expression profile of acute graft-versus-host disease.
    Buzzeo MP; Yang J; Casella G; Reddy V
    Cell Transplant; 2008; 17(5):489-94. PubMed ID: 18714668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation.
    McGuirk J; Hao G; Hou W; Abhyankar S; Williams C; Yan W; Yuan J; Guan X; Belt R; Dejarnette S; Wieman J; Yan Y
    J Hematol Oncol; 2009 Apr; 2():17. PubMed ID: 19379511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative Analysis of Long Noncoding RNAs in Patients with Graft-versus-Host Disease.
    Wang F; Luo L; Gu Z; Yang N; Wang L; Gao C
    Acta Haematol; 2020; 143(6):533-551. PubMed ID: 32289782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
    Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
    Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
    Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
    J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
    Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
    Front Immunol; 2019; 10():1879. PubMed ID: 31507582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances and research progress in biomarkers for chronic graft versus host disease.
    Ji R; Li Y; Huang R; Xiong J; Wang X; Zhang X
    Crit Rev Oncol Hematol; 2023 Jun; 186():103993. PubMed ID: 37061073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
    Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
    Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.